Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches

Journal of Chemical Information and Modeling

Volumn 53, Issue 9, 2013, Pages 2376-2389

  Sun, Huiyong ^a   Li, Youyong ^a   Li, Dan ^b   Hou, Tingjun ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BINDING ENERGY; DISEASES; ENTROPY; ENZYMES; PATIENT MONITORING; PATIENT TREATMENT;

ADAPTIVE BIASING FORCES; ANAPLASTIC LYMPHOMA KINASE; CONFORMATIONAL ENTROPY; ENERGY DECOMPOSITION ANALYSIS; FOOD AND DRUG ADMINISTRATION; FREE-ENERGY CALCULATIONS; NON SMALL CELL LUNG CANCER; POTENTIALS OF MEAN FORCES;

FREE ENERGY;

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CRIZOTINIB; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

CHEMICAL STRUCTURE; CHEMISTRY; DRUG RESISTANCE; ENTROPY; GENETICS; METABOLISM; MOVEMENT (PHYSIOLOGY); MUTATION; PROTEIN CONFORMATION; ARTICLE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ENTROPY; MODELS, MOLECULAR; MOVEMENT; MUTATION; PROTEIN CONFORMATION; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84884570151     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci400188q     Document Type: Article

References (72)

1. Crystal, A. S.; Shaw, A. T. New targets in advanced NSCLC: EML4-ALK Clin. Adv. Hematol. Oncol. 2011, 9, 207-214
2. Kwak, E. L.; Bang, Y. J.; Camidge, D. R.; Shaw, A. T.; Solomon, B.; Maki, R. G.; Ou, S. H. I.; Dezube, B. J.; Jänne, P. A.; Costa, D. B. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med. 2010, 363, 1693-1703
3. Lovly, C. M.; Carbone, D. P. Lung cancer in 2010: One size does not fit all Nat. Rev. Clin. Oncol. 2011, 8, 68-70
4. Mok, T. S. K. Personalized medicine in lung cancer: what we need to know Nat. Rev. Clin. Oncol. 2011, 8, 661-668
5. Weickhardt, A. J.; Camidge, D. R. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence J. Clin. Invest. 2011, 1, 1119-1126
6. Feliciano, P. Acquired resistance in lung cancer Nat. Genet. 2012, 44, 241-241
7. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 2007, 448, 561-566
8. Christensen, J. G.; Zou, H. Y.; Arango, M. E.; Li, Q.; Lee, J. H.; McDonnell, S. R.; Yamazaki, S.; Alton, G. R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol. Cancer Ther. 2007, 6, 3314-3322
9. Gerber, D. E.; Minna, J. D. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time Cancer cell 2010, 18, 548-551
10. Hallberg, B.; Palmer, R. H. Crizotinib -latest champion in the cancer wars? N. Engl. J. Med. 2010, 363, 1760-1762
11. Choi, Y. L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N. Engl. J. Med. 2010, 363, 1734-1739
12. Sasaki, T.; Okuda, K.; Zheng, W.; Butrynski, J.; Capelletti, M.; Wang, L.; Gray, N. S.; Wilner, K.; Christensen, J. G.; Demetri, G. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers Cancer Res. 2010, 70, 10038-10043
13. Sasaki, T.; Koivunen, J.; Ogino, A.; Yanagita, M.; Nikiforow, S.; Zheng, W.; Lathan, C.; Marcoux, J. P.; Du, J.; Okuda, K. A novel ALK sondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors Cancer Res. 2011, 71, 6051-6060
14. Doebele, R. C.; Pilling, A. B.; Aisner, D. L.; Kutateladze, T. G.; Le, A. T.; Weickhardt, A. J.; Kondo, K. L.; Linderman, D. J.; Heasley, L. E.; Franklin, W. A. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer Clin. Cancer Res. 2012, 18, 1472-1482
15. Katayama, R.; Shaw, A. T.; Khan, T. M.; Mino-Kenudson, M.; Solomon, B. J.; Halmos, B.; Jessop, N. A.; Wain, J. C.; Yeo, A. T.; Benes, C. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers Sci. Transl. Med. 2012, 4, 120ra117
16. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Jänne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 2005, 352, 786-792
17. Katayama, R.; Khan, T. M.; Benes, C.; Lifshits, E.; Ebi, H.; Rivera, V. M.; Shakespeare, W. C.; Iafrate, A. J.; Engelman, J. A.; Shaw, A. T. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 7535-7540
18. Lovly, C. M.; Pao, W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance Sci. Transl. Med. 2012, 4, 120ps2
19. Bresler, S. C.; Wood, A. C.; Haglund, E. A.; Courtright, J.; Belcastro, L. T.; Plegaria, J. S.; Cole, K.; Toporovskaya, Y.; Zhao, H.; Carpenter, E. L. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma Sci. Transl. Med. 2011, 3, 108ra114
20. Berry, T.; Luther, W.; Bhatnagar, N.; Jamin, Y.; Poon, E.; Sanda, T.; Pei, D.; Sharma, B.; Vetharoy, W. R.; Hallsworth, A. The ALK F1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma Cancer cell 2012, 22, 117-130
21. Sun, H. Y.; Ji, F. Q. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK Biochem. Biophys. Res. Commun. 2012, 423, 319-324
22. Shen, L.; Ji, H. More on crizotinib N. Engl. J. Med. 2011, 364, 777-778
23. Cui, J. J.; Tran-Dubé, M.; Shen, H.; Nambu, M.; Kung, P. P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I. Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) J. Med. Chem. 2011, 54, 6342-6363
24. Lee, C.; Jia, Y.; Li, N.; Sun, X.; Ng, K.; Ambing, E.; Gao, M.; Hua, S.; Chen, C.; Kim, S. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain Biochem. J. 2010, 430, 425-437
25. Frisch, M.; Trucks, G.; Schlegel, H.; Scuseria, G.; Robb, M.; Cheeseman, J.; Montgomery, Jr, J.; Vreven, T.; Kudin, K.; Burant, J. Gaussian 03; Gaussian, Inc.: Wallingford, CT, 2004.
26. Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model J. Phys. Chem. 1993, 97, 10269-10280
27. Wang, J.; Wang, W.; Kollman, P. A.; Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations J. Mol. Graph. Model. 2006, 25, 247-260
28. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25, 1157-1174
29. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins: Struct., Funct., Bioinf. 2006, 65, 712-725
30. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935
31. Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R. D.; Kale, L.; Schulten, K. Scalable molecular dynamics with NAMD J. Comput. Chem. 2005, 26, 1781-1802
32. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N log(N) method for Ewald sums in large systems J. Chem. Phys. 1993, 98, 10089-10092
33. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes J. Comput. Phys. 1977, 23, 327-341
34. Feller, S. E.; Zhang, Y.; Pastor, R. W.; Brooks, B. R. Constant-pressure molecular-dynamics simulation-the Langevin piston method J. Chem. Phys. 1995, 103, 4613-4621
35. Darve, E.; Rodríguez-Gómez, D.; Pohorille, A. Adaptive biasing force method for scalar and vector free energy calculations J. Chem. Phys. 2008, 128, 144120-144132
36. Hénin, J.; Fiorin, G.; Chipot, C.; Klein, M. L. Exploring multidimensional free energy landscapes using time-dependent biases on collective variables J. Chem. Theory Comput. 2009, 6, 35-47
37. Cai, W.; Sun, T.; Liu, P.; Chipot, C.; Shao, X. Inclusion Mechanism of Steroid Drugs into β-Cyclodextrins. Insights from Free Energy Calculations J. Phys. Chem. B 2009, 113, 7836-7843
38. Dehez, F.; Pebay-Peyroula, E.; Chipot, C. Binding of ADP in the mitochondrial ADP/ATP carrier is driven by an electrostatic funnel J. Am. Chem. Soc. 2008, 130, 12725-12733
39. Kekenes-Huskey, P. M.; Lindert, S.; McCammon, J. A. Molecular Basis of Calcium-Sensitizing and Desensitizing Mutations of the Human Cardiac Troponin C Regulatory Domain: A Multi-Scale Simulation Study PLoS Comput. Biol 2012, 8, e1002777
40. Yang, L. J.; Zou, J.; Xie, H. Z.; Li, L. L.; Wei, Y. Q.; Yang, S. Y. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl PloS One 2009, 4, e8470
41. Petřek, M.; Otyepka, M.; Banáš, P.; Košinová, P.; Koča, J.; Damborský, J. CAVER: a new tool to explore routes from protein clefts, pockets and cavities BMC Bioinf. 2006, 7, 316-325
42. Doudou, S.; Burton, N. A.; Henchman, R. H. Standard free energy of binding from a one-dimensional potential of mean force J. Chem. Theory. Comput. 2009, 5, 909-918
43. Gumbart, J. C.; Roux, B. t.; Chipot, C. Standard Binding Free Energies from Computer Simulations: What Is the Best Strategy? J. Chem. Theory Comput. 2012, 9, 794-802
44. Woo, H.-J.; Roux, B. Calculation of absolute protein-ligand binding free energy from computer simulations Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 6825-6830
45. Deng, Y.; Roux, B. Computations of standard binding free energies with molecular dynamics simulations J. Phys. Chem. B 2009, 113, 2234-2246
46. Li, L.; Li, Y.; Zhang, L.; Hou, T. Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase J. Chem. Inf. Model. 2012, 52, 2715-2729
47. Hou, T.; Yu, R. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance J. Med. Chem. 2007, 50, 1177-1188
48. Zhang, J.; Hou, T.; Wang, W.; Liu, J. S. Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 1321-1326
49. Liu, H.; Yao, X.; Wang, C.; Han, J. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase Mol. Pharm. 2010, 7, 894-904
50. Beveridge, D. L.; DiCapua, F. Free energy via molecular simulation: applications to chemical and biomolecular systems Annu. Re V. Biophys. Biomol. Struct. 1989, 18, 431-492
51. Gohlke, H.; Klebe, G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors Angew. Chem., Int. Ed. Engl. 2002, 41, 2644-2676
52. Jo, S.; Jiang, W.; Lee, H. S.; Roux, B.; Im, W. CHARMM-GUI Ligand Binder for Absolute Binding Free Energy Calculations and Its Application J. Chem. Inf. Model. 2013, 53, 267-277
53. Jorgensen, W. L.; Thomas, L. L. Perspective on free-energy perturbation calculations for chemical equilibria J. Chem. Theory Comput. 2008, 4, 869-876
54. Homeyer, N.; Gohlke, H. Free Energy Calculations by the Molecular Mechanics Poisson-Boltzmann Surface Area Method Mol. Inf. 2012, 31, 114-122
55. Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models Acc. Chem. Res. 2000, 33, 889-897
56. Wang, J. M.; Hou, T. J.; Xu, X. J. Recent advances in free energy calculations with a combination of molecular mechanics and continuum models Curr. Comput.-Aided Drug Des. 2006, 2, 287-306
57. Onufriev, A.; Bashford, D.; Case, D. A. Exploring protein native states and large-scale conformational changes with a modified generalized born model Proteins: Struct., Funct., Bioinf. 2004, 55, 383-394
58. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the MM/PBSA and MM/GBSA methods: I. The accuracy of binding free energy calculations based on molecular dynamics simulations J. Chem. Inf. Model. 2011, 51, 69-82
59. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking J. Comput. Chem. 2011, 32, 866-877
60. Weiser, J.; Shenkin, P. S.; Still, W. C. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) J. Comput. Chem. 1999, 20, 217-230
61. Brooks, B.; Karplus, M. Harmonic dynamics of proteins: normal modes and fluctuations in bovine pancreatic trypsin inhibitor Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 6571-6575
62. Miller, B. R., III; McGee, T. D.; Swails, J. M.; Homeyer, N.; Gohlke, H.; Roitberg, A. E. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations J. Chem. Theory Comput. 2012, 8, 3314-3321
63. Lu, H.; Tonge, P. J. Drug-target residence time: critical information for lead optimization Curr. Opin. Chem. Biol. 2010, 14, 467-474
64. Tummino, P. J.; Copeland, R. A. Residence Time of Receptor-Ligand Complexes and Its Effect on Biological Function Biochemistry 2008, 47, 5481-5492
65. Masson, P.; Froment, M.; Bartels, C.; Lockridge, O. Importance of aspartate-70 in organophosphate inhibition, oxime re-activation and aging of human butyrylcholinesterase Biochem. J. 1997, 325, 53-61
66. Amadei, A.; Linssen, A.; Berendsen, H. J. C. Essential dynamics of proteins Proteins: Struct., Funct., Bioinf. 1993, 17, 412-425
67. Arcangeli, C.; Bizzarri, A. R.; Cannistraro, S. Concerted motions in copper plastocyanin and azurin: an essential dynamics study Biophys. Chem. 2001, 90, 45-56
68. Chillemi, G.; Falconi, M.; Amadei, A.; Zimatore, G.; Desideri, A.; Di Nola, A. The essential dynamics of Cu, Zn superoxide dismutase: suggestion of intersubunit communication Biophys. J. 1997, 73, 1007-1018
69. Schlitter, J. Estimation of absolute and relative entropies of macromolecules using the covariance matrix Chem. Phys. Lett. 1993, 215, 617-621
70. Hou, T.; McLaughlin, W. A.; Wang, W. Evaluating the potency of HIV-1 protease drugs to combat resistance Proteins: Struct., Funct., Bioinf. 2008, 71, 1163-1174
71. Hou, T.; Zhang, W.; Wang, J.; Wang, W. Predicting drug resistance of the HIV-1 protease using molecular interaction energy components Proteins: Struct., Funct., Bioinf. 2009, 74, 837-846
72. Pan, D. B.; Sun, H. J.; Shen, Y. L.; Liu, H. X.; Yao, X. J. Exploring the molecular basis of dsRNA recognition by NS1 protein of influenza A virus using molecular dynamics simulation and free energy calculation Antiviral Res. 2011, 92, 424-433